论文部分内容阅读
目的:阐述I型5α还原酶(SRD5A1)在前列腺癌中的表达及意义。方法:检索ONCOMINE数据库中关于SRD5A1的信息,并对目前数据库中资料进行2次分析,对其在前列腺癌中的作用进行meta分析。结果:ONCOMINE数据库中共收集了992项不同类型SRD5A1的研究结果,关于SRD5A1表达有统计学差异的结果有239项,其中SRD5A1表达增高的有157项,表达降低的有82项。前列腺癌中高表达的有11项、低表达的有3项。共有18项研究涉及SRD5A1在前列腺癌组织和正常组织中的表达,包括1 068例样本。SRD5A1在前列腺癌中的表达量高于正常组织(P<0.05)。而在其中3项研究中,SRD5A1不仅在前列腺癌中高表达,并且随着前列腺癌的转移,SRD5A1的表达量逐渐增高(P<0.05)。不仅如此,在2项有预后数据的研究中,高表达SRD5A1的患者术后生化复发率和总体死亡率较高,低表达SRD5A1的患者术后预后较好(P<0.05)。结论:SRD5A1在前列腺癌组织,尤其是在转移性前列腺癌和去势抵抗性前列腺癌高表达,且与前列腺癌预后有关,其有可能成为前列腺癌肿瘤药物的重要靶点。
Objective: To elucidate the expression and significance of type I 5α reductase (SRD5A1) in prostate cancer. Methods: The information about SRD5A1 in ONCOMINE database was searched, and the data in the database were analyzed twice and the role of SRD5A1 in prostate cancer was analyzed by meta-analysis. RESULTS: A total of 992 SRD5A1 studies were collected in the ONCOMINE database. There were 239 statistically significant differences in SRD5A1 expression among which 157 were increased in SRD5A1 and 82 were decreased. Prostate cancer in the high expression of 11, low expression of 3. A total of 18 studies involved the expression of SRD5A1 in prostate cancer tissues and normal tissues, including 1 068 samples. The expression of SRD5A1 in prostate cancer was higher than that in normal tissues (P <0.05). In 3 of these studies, SRD5A1 was not only highly expressed in prostate cancer, but also increased with the metastasis of prostate cancer (P <0.05). In addition, in two studies with prognostic data, patients with high SRD5A1 expression had a higher postoperative biochemical recurrence rate and overall mortality, and patients with low SRD5A1 expression had a better postoperative prognosis (P <0.05). CONCLUSIONS: SRD5A1 is overexpressed in prostate cancer tissues, especially in metastatic prostate cancer and castration-resistant prostate cancer, and is associated with the prognosis of prostate cancer. It may be an important target for prostate cancer drugs.